Allergan PLC (AGN)

Common-Size Income Statement

Difficulty: Beginner

Annual Data

Quarterly Data

Allergan PLC, Common-Size Consolidated Income Statement

12 months ended	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013
Net revenues
Cost of sales, excludes amortization and impairment of acquired intangibles including product rights
Gross profit	%	%	%	%	%
Research and development
Selling and marketing
General and administrative
Amortization
Goodwill impairments
In-process research and development impairments
Loss on assets held for sale
Asset sales and impairments, net
Operating loss	%	%	%	%	%
Interest income
Interest expense
Teva Share Activity
Debt extinguishment costs as part of the debt tender offer
Debt extinguishment other
Other-than-temporary impairments
Dividend income
Naurex recovery
Forward sale of Teva shares
Pfizer termination fee, Allergan plc only
Bridge loan commitment fee
Interest rate lock
Gain (loss) on sale of assets
Other
Other income (expense), net	%	%	%	%	%
Loss before income taxes and noncontrolling interest	%	%	%	%	%
Provision (benefit) for income taxes
Net loss from continuing operations, net of tax	%	%	%	%	%
Income (loss) from discontinued operations, net of tax
Net income (loss)	%	%	%	%	%
(Income) loss attributable to noncontrolling interest
Net income (loss) attributable to shareholders	%	%	%	%	%
Dividends on preferred shares
Net income (loss) attributable to ordinary shareholders	%	%	%	%	%

	Allergan PLC	Other companies (not purchased previously)
Financial Statements
Common-Size Financial Statements
Ratios
Relative Valuation
Discounted Cash Flow (DCF) Valuation
Economic Value Added (EVA)
Long-term Trends
Analysis
Financial Reporting Quality

	All companies
Financial Statements
Common-Size Financial Statements
Ratios
Relative Valuation
Discounted Cash Flow (DCF) Valuation
Economic Value Added (EVA)
Long-term Trends
Analysis
Financial Reporting Quality